Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran, chemically (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a rigorously validated hypolipidemic agent acting as a selective agonist for HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) G-protein coupled receptors (Ye et al., 2025). High-resolution cryo-EM studies have confirmed its binding mode and receptor selectivity at atomic detail. Acifran demonstrates solubility under 21.82 mg/ml in ethanol or DMSO and is stable at -20°C for short-term use (APExBIO). Its use is restricted to laboratory research, supporting advanced studies in lipid regulation and metabolic disorders. Recent structural benchmarks position Acifran as a reference ligand for dissecting GPCR-ligand interactions (PrecisionFDA).

Biological Rationale

Lipid metabolism involves a tightly regulated network of signaling pathways, many mediated by G-protein coupled receptors (GPCRs). The hydroxycarboxylic acid receptors HM74A (GPR109A/HCAR2) and GPR109B (HCAR3) are key modulators of lipid mobilization, oxidation, and anti-lipolytic responses (Ye et al., 2025). Activation of these receptors is clinically relevant for treating dyslipidemia, hyperlipidemia, and atherosclerosis. Acifran selectively targets HM74A and GPR109B, making it a precise tool for mapping lipid signaling and metabolic regulation without the confounding effects seen in less selective agents. Unlike some agonists, Acifran’s lack of cutaneous flushing renders it suitable for mechanistic studies, distinguishing HCAR3-specific signaling from HCAR2-mediated side effects.

Mechanism of Action of Acifran

Acifran is a small-molecule ligand with the chemical formula C₁₂H₁₀O₄ and a molecular weight of 218.21 g/mol (APExBIO). It binds the orthosteric pocket of HM74A (GPR109A/HCAR2) and GPR109B (HCAR3), stabilizing their active conformations (Ye et al., 2025). Cryo-EM structural data (PDB: 9JKX for HCAR3, 9JKY for HCAR2) reveal that Acifran's selectivity is governed by π–π stacking interactions with F107^3.32 in HCAR3 and pocket size differences. This selectivity allows researchers to dissect signaling cascades downstream of each receptor. Upon activation, these GPCRs couple to Gi proteins, leading to reduced cyclic AMP (cAMP) levels and downstream modulation of lipid metabolism genes. Acifran’s selectivity profile enables targeted analysis of lipid lowering and anti-inflammatory pathways, distinguishing effects mediated by HCAR2 vs. HCAR3.

Evidence & Benchmarks

• Acifran binds directly to HCAR2 and HCAR3 with atomic-level resolution, as shown in cryo-EM structures (PDB 9JKX, 9JKY) (Ye et al., 2025).
• Ligand selectivity is attributed to π–π stacking with F107^3.32 and unique pocket residues in HCAR3 (Ye et al., 2025, Fig. 2).
• cAMP inhibition assays confirm Acifran’s functional agonism in HEK-293 cells expressing HCAR2/HCAR3 (Ye et al., 2025, Methods/Results).
• Acifran displays solubility of <21.82 mg/ml in ethanol and DMSO under laboratory conditions (APExBIO).
• Storage at -20°C preserves Acifran’s integrity for short-term experimental use (APExBIO).
• Validated as a tool for precise mapping of lipid signaling in metabolic disorder research (PrecisionFDA).

Applications, Limits & Misconceptions

Acifran is primarily used in laboratory research to:

• Elucidate GPCR-ligand interactions and structural biology of HCAR2/HCAR3.
• Dissect lipid metabolism and anti-lipolytic signaling in cell-based models.
• Serve as a reference compound in screening for novel hypolipidemic agents.
• Advance studies of metabolic disorders, including dyslipidemia and atherosclerosis.

For a comparative perspective, see this structured review, which details Acifran’s mechanism and benchmarks. This article extends those findings with updated structural evidence and workflow integration guides.

Common Pitfalls or Misconceptions

1. Acifran is not a diagnostic or therapeutic agent; its use is restricted to laboratory research (APExBIO).
2. It does not activate unrelated GPCRs or non-hydroxycarboxylic acid receptors (Ye et al., 2025).
3. Overexposure or long-term solution storage (>1 week) may lead to compound degradation and reduced activity (APExBIO).
4. Acifran's selectivity may not fully translate to non-human orthologs without validation (Ye et al., 2025).
5. It is unsuitable for in vivo human or animal therapeutic use.

For more on specificity and troubleshooting, this scenario-driven article discusses laboratory challenges and solutions, while this article focuses on recent structural validation and practical parameters.

Workflow Integration & Parameters

Acifran (SKU B6848) from APExBIO is supplied as an off-white solid. The recommended protocol involves dissolving the compound in DMSO or ethanol at concentrations below 21.82 mg/ml. Solutions should be freshly prepared or stored at -20°C for short-term use only (APExBIO). For GPCR signaling assays, HEK-293 or Sf9 cell expression systems are standard (Ye et al., 2025). Cryo-EM or biochemical assays can be performed with reference to the deposited structures (PDB 9JKX, 9JKY). For further guidance, this article discusses workflow nuances and reproducibility; this current review updates the integration parameters based on latest cryo-EM data.

Conclusion & Outlook

Acifran remains a reference standard for studying HM74A/GPR109A and GPR109B signaling in lipid metabolism research. Its atomic-level characterization facilitates precise experimental design in GPCR biology. As structural insights deepen, Acifran will continue to anchor the development of targeted hypolipidemic agents and the elucidation of lipid regulation pathways. For up-to-date protocols and quality assurance, consult the Acifran product page at APExBIO.